Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBITDA (2023 - 2025)

Historic EBITDA for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to -$3.6 million.

  • Immunocore Holdings' EBITDA fell 12978.39% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year decrease of 2306.14%. This contributed to the annual value of -$48.6 million for FY2024, which is 3176.68% down from last year.
  • Immunocore Holdings' EBITDA amounted to -$3.6 million in Q3 2025, which was down 12978.39% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' EBITDA ranged from a high of $12.0 million in Q3 2024 and a low of -$51.1 million during Q4 2021
  • For the 5-year period, Immunocore Holdings' EBITDA averaged around -$16.6 million, with its median value being -$11.3 million (2023).
  • Examining YoY changes over the last 5 years, Immunocore Holdings' EBITDA showed a top increase of 18531.86% in 2024 and a maximum decrease of 450856.64% in 2024.
  • Over the past 5 years, Immunocore Holdings' EBITDA (Quarter) stood at -$51.1 million in 2021, then surged by 36.43% to -$32.5 million in 2022, then skyrocketed by 98.24% to -$572000.0 in 2023, then tumbled by 4508.57% to -$26.4 million in 2024, then soared by 86.46% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, -$3.8 million for Q2 2025, and $5.7 million during Q1 2025.